carbenoxolone sodium has been researched along with Hyperinsulinism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campello, RS; Machado, UF; Mori, RC; Poças da Silva, T | 1 |
| Hachey, DL; Hasty, AH; Nuotio-Antar, AM | 1 |
2 other study(ies) available for carbenoxolone sodium and Hyperinsulinism
| Article | Year |
|---|---|
Carbenoxolone enhances peripheral insulin sensitivity and GLUT4 expression in skeletal muscle of obese rats: Potential participation of UBC9 protein.
Topics: Animals; Anti-Ulcer Agents; Carbenoxolone; Gene Expression Regulation; Glucose Transporter Type 4; Hyperinsulinism; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Rats; Rats, Wistar; Ubiquitin-Conjugating Enzymes | 2019 |
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Agouti Signaling Protein; Animals; Atherosclerosis; Blood Pressure; Body Weight; Carbenoxolone; Corticosterone; Energy Metabolism; Fatty Liver; Female; Hyperinsulinism; Hyperlipidemias; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Receptors, LDL | 2007 |